Giles Scientific designs, manufactures, and sells microbiology imaging systems. Giles Scientific was incorporated in 1984 in New York City after US-FDA 510k clearance to market BIOMIC to clinical microbiology labs for reading antibiotic disk diffusion tests. TRINITY was introduced in 1985 to read and interpret newly manufactured lots of antibiotics USP/EP/JP agar diffusion potency methods in pharmaceutical QA labs.

Since then, we developed software modules to read and interpret: MIC strips (Etest, MIC Test Strip), ID panels (RapID, API, Liofilchem), broth microdilution plates (Sensititre, MicroScan, Bruker, Custom), agar dilution, chromogenic agar, urine screen, and colony count plates. LIS/middleware connectivity and on-screen verification of test results is a key feature of all software modules.

The complex intelligence required to accurately read and interpret these assays was added to our software through continuous R&D, and interacting with: our customers, CLSI, EUCAST, WHO, CDC, AST-ID device manufacturers, and global microbiology experts. The evolution of antibiotic resistance in bacteria and fungi requires continuous software updates to include new drugs, new organisms, new mechanisms of resistance, new interpretive guidelines, and changing expert rules.

Giles Scientific is a US-FDA registered device manufacturer and adheres to the highest standards of manufacturing, support and service. We are an ISO 13485 certified company, having received certification for Quality Management Systems applicable to the design and assembly of lab equipment and software for the medical device industry. Giles Scientific also received IVDR approval for BIOMIC V3 sales in Europe.

We relocated to California in 1998, and support customers in clinical, veterinary, public health, research and industrial labs in 100+ countries. Many journal publications and customer testimonials document our excellent service and performance.

My background in academia, hospitals, public health, and pharmaceutical/antibiotic and device development made me acutely aware of microbiologists’ need for assistance to better read and interpret these challenging assays.

David L. Gibbs, Ph.D. ABMM
CEO & Founder
Santa Barbara, California, USA